Rational vaccinology with spherical nucleic acids.
cancer vaccinology
immunotherapy
nanotechnology
spherical nucleic acids
structural design
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
21 05 2019
21 05 2019
Historique:
pubmed:
10
5
2019
medline:
31
3
2020
entrez:
10
5
2019
Statut:
ppublish
Résumé
In the case of cancer immunotherapy, nanostructures are attractive because they can carry all of the necessary components of a vaccine, including both antigen and adjuvant. Herein, we explore how spherical nucleic acids (SNAs), an emerging class of nanotherapeutic materials, can be used to deliver peptide antigens and nucleic acid adjuvants to raise immune responses that kill cancer cells, reduce (or eliminate) tumor growth, and extend life in three established mouse tumor models. Three SNA structures that are compositionally nearly identical but structurally different markedly vary in their abilities to cross-prime antigen-specific CD8
Identifiants
pubmed: 31068463
pii: 1902805116
doi: 10.1073/pnas.1902805116
pmc: PMC6535021
doi:
Substances chimiques
Cancer Vaccines
0
Nucleic Acids
0
Types de publication
Comparative Study
Evaluation Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
10473-10481Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM105538
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA199091
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Cell Sci. 1992 Nov;103 ( Pt 3):857-62
pubmed: 1478975
Nature. 2004 Apr 1;428(6982):487-92
pubmed: 15057821
Science. 2006 Feb 3;311(5761):622-7
pubmed: 16456071
Science. 2006 May 19;312(5776):1027-30
pubmed: 16709779
Pharm Res. 2007 Jun;24(6):1029-46
pubmed: 17385025
Clin Pharmacol Ther. 2008 May;83(5):761-9
pubmed: 17957183
Nat Nanotechnol. 2007 Dec;2(12):751-60
pubmed: 18654426
Nat Mater. 2011 May;10(5):389-97
pubmed: 21499315
Adv Drug Deliv Rev. 2013 Jan;65(1):21-3
pubmed: 22580334
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11975-80
pubmed: 22773805
Curr Opin Immunol. 2013 Apr;25(2):238-45
pubmed: 23337254
Nat Mater. 2013 Nov;12(11):967-77
pubmed: 24150415
Nat Mater. 2013 Nov;12(11):978-90
pubmed: 24150416
Sci Transl Med. 2013 Oct 30;5(209):209ra152
pubmed: 24174328
Nat Rev Cancer. 2014 Feb;14(2):135-46
pubmed: 24457417
Cancer Res. 2015 Feb 1;75(3):519-31
pubmed: 25502838
Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):3892-7
pubmed: 25775582
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
ACS Nano. 2015 Jun 23;9(6):5627-30
pubmed: 26100220
Chem Rev. 2015 Oct 14;115(19):11109-46
pubmed: 26154342
Ann Oncol. 2015 Dec;26(12):2375-91
pubmed: 26371282
Adv Drug Deliv Rev. 2016 Mar 1;98:3-18
pubmed: 26546465
Nat Rev Cancer. 2016 Jan;16(1):56-66
pubmed: 26694936
Curr Opin Biotechnol. 2016 Aug;40:1-8
pubmed: 26896596
Nat Rev Clin Oncol. 2016 May;13(5):273-90
pubmed: 26977780
Nat Rev Clin Oncol. 2016 Aug;13(8):473-86
pubmed: 27141885
Oncotarget. 2016 Sep 20;7(38):61069-61080
pubmed: 27517629
Cell Rep. 2016 Dec 6;17(10):2503-2511
pubmed: 27926855
J Immunol. 2017 Feb 1;198(3):1365-1375
pubmed: 28011934
Biomaterials. 2017 Jul;132:48-58
pubmed: 28407494
Nat Nanotechnol. 2017 Jul;12(7):648-654
pubmed: 28436963
Small. 2018 Feb;14(5):
pubmed: 29226611
J Am Chem Soc. 2018 Jan 31;140(4):1227-1230
pubmed: 29356509
Curr Opin Biotechnol. 2018 Aug;52:80-88
pubmed: 29597075
BioDrugs. 2018 Aug;32(4):297-309
pubmed: 29959665